Compugen (NASDAQ:CGEN) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a report released on Thursday morning.

Separately, Truist Financial dropped their target price on Compugen from $5.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, May 21st.

Compugen Trading Down 4.5 %

Compugen stock opened at $1.68 on Thursday. Compugen has a twelve month low of $0.53 and a twelve month high of $3.03. The stock’s fifty day simple moving average is $2.05 and its 200-day simple moving average is $2.15. The firm has a market capitalization of $145.52 million, a P/E ratio of -8.84 and a beta of 2.71.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. The business had revenue of $2.56 million during the quarter, compared to analysts’ expectations of $2.79 million. Sell-side analysts predict that Compugen will post 0.05 earnings per share for the current year.

Institutional Trading of Compugen

An institutional investor recently bought a new position in Compugen stock. Heron Bay Capital Management bought a new position in shares of Compugen Ltd. (NASDAQ:CGEN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.